Validation of urinary CXCL10 As a marker of borderline, subclinical, and clinical tubulitis

Transplantation

Volumn 92, Issue 8, 2011, Pages 878-882

  Ho, Julie ^a,b   Rush, David N ^a   Karpinski, Martin ^a   Storsley, Leroy ^a   Gibson, Ian W ^a   Bestland, Jennifer ^b   Gao, Ang ^b   Stefura, William ^a   Hayglass, Kent T ^a   Nickerson, Peter W ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Chemokine; CXCL10; Kidney transplant; Rejection; Urine biomarker

Indexed keywords

CREATININE; GAMMA INTERFERON INDUCIBLE PROTEIN 10;

ADULT; ARTICLE; BORDERLINE TUBULITIS; CLINICAL TUBULITIS; CONTROLLED STUDY; CREATININE URINE LEVEL; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SUBCLINICAL TUBULITIS; URINALYSIS; VALIDATION STUDY;

ADULT; ATROPHY; BIOLOGICAL MARKERS; CHEMOKINE CXCL10; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; KIDNEY TUBULES; LOGISTIC MODELS; MALE; MIDDLE AGED; NEPHRITIS;

EID: 80054771957     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31822d4de1     Document Type: Article

References (32)

1. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527.
2. Rush DN, Henry SF, Jeffrey JR, et al. Histological findings in early routine biopsies of stable renal allograft recipients. Transplantation 1994; 57: 208.
3. Rush D, Nickerson P, Gough J, et al. Beneficial effects of treatment of early subclinical rejection: A randomized study. J AmSoc Nephrol 1998; 9: 2129.
4. Rush D, Arlen D, Boucher A, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: A randomized study. Am J Transplant 2007; 7: 2538.
5. Qin S, Rottman JB, Myers P, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101: 746.
6. el-Sawy T, Fahmy NM, Fairchild RL. Chemokines: Directing leukocyte infiltration into allografts. Curr Opin Immunol 2002; 14: 562.
7. Dufour JH, Dziejman M, Liu MT, et al. IFN-gamma-inducible protein 10 (IP10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002; 168: 3195.
8. Kanmaz T, Feng P, Torrealba J, et al. Surveillance of acute rejection in baboon renal transplantation by elevation of interferon- inducible protein-10 and monokine induced by interferon- in urine. Transplantation 2004; 78: 1002.
9. Tatapudi RR, Muthukumar T, Dadhania D, et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int 2004; 65: 2390.
10. Schaub S, Nickerson P, Rush D, et al. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplant 2009; 9: 1347.
11. Hu H, Kwun J, Aizenstein BD, Knechtle SJ. Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine. Transplantation 2009; 87: 1814.
12. Hu H, Aizenstein BD, Puchalski A, et al. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant 2004; 4: 432.
13. Matz M, Beyer J, Wunsch D, et al. Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and longterm graft function. Kidney Int 2006; 69: 1683.
14. Hauser IA, Spiegler S, Kiss E, et al. Prediction of acute renal allograft rejection by urinary monokine induced by IFN- (MIG). J Am Soc Nephrol 2005; 16: 1849.
15. Ho J, Rush DN, Gibson IW, et al. Early urinary CCL2 is associated with the later development of interstitial fibrosis and tubular atrophy in renal allografts. Transplantation 2010; 90: 394.
16. Lazzeri E, Rotondi M, Mazzinghi B, et al. High CXCL10 expression rejected kidneys and predictive role of pretransplant serum CXCL10 for acute rejection and chronic allograft nephropathy. Transplantation 2005; 79: 1215.
17. Rotondi M, Rosati A, Buonamano A, et al. High pretransplant serum levels of CXCL10/IP-10 are related to increased risk of renal allograft failure. Am J Transplant 2004; 4: 1466.
18. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354: 610.
19. Romagnani P, Lasagni L, Annunziato F, et al. CXC chemokines: The regulatory link between inflammation and angiogenesis. Trends Immunol 2004; 25: 201.
20. Datta D, Dormond O, Basu A, et al. Heme oxygenase-1 modulates the expression of the anti-angiogenic chemokine CXCL-10 in renal tubular epithelial cells. Am J Physiol Renal Physiol 2007; 293: F1222.
21. Kanakiriya SKR, Croatt AJ, Haggard JJ, et al. Heme: A novel inducer of MCP-1 through HO-dependent and HO-independent mechanisms. Am J Physiol Renal Physiol 2003; 284: F546.
22. Hancock WW, Lu B, Gao W, et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000; 192: 1515.
23. Akashi S, Sho M, Kashizuka H, et al. A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection. Transplantation 2005; 80: 378.
24. Rosenblum JM, Zhang Q-W, Siu G, et al. CXCR3 antagonism impairs the development of donor-reactive, IFN-α-producing effectors and prolongs allograft survival. Transplantation 2009; 87: 360.
25. He S, Cao Q, Qiu Y, et al.Anew approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody. J Immunol 2008; 181: 7581.
26. Hancock WW, Gao W, Csizmadia V, et al. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 2001; 193: 975.
27. Byrne FR, Winters A, Brankow D, et al. An antibody to IP-10 is a potent antagonist of cell migration in vitro and in vivo and does not affect disease in several animal models of inflammation. Autoimmunity 2009; 42: 171.
28. Kwun J, Hazinedaroglu SM, Schadde E, et al. Unaltered graft survival and intragraft lymphocytes infiltration in the cardiac allograft of CXCR3/ mouse recipients. Am J Transplant 2008; 8: 1593.
29. Zerwes HG, Li J, Kovarik J, et al. The chemokine receptor CXCR3 is not essential for acute cardiac allograft rejection in mice and rats. Am J Transplant 2008; 8: 1604.
30. Ho J, Lucy M, Krokhin O, et al. Mass spectrometry-based proteomic analysis of urine in acute kidney injury following cardiopulmonary bypass: A nested case-control study. Am J Kidney Dis 2009; 53: 584.
31. Solez K, Colvin RB, Racusen LC, et al. Banff 07 Classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753.
32. Stefura WP, Campbell JD, Douville R, et al. Ultrasensitive ELISA for measurement of human cytokine responses in primary culture. Methods Mol Med 2008; 138: 107.